ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study

Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group

doi:10.1177/01410768231214341

ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study

Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators, Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	JRSM cardiovascular disease
Early online date	12 Dec 2023
DOIs	https://doi.org/10.1177/01410768231214341
Publication status	E-pub ahead of print - 12 Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/01410768231214341Licence: CC BY

Cite this

Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators, & Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group (2023). ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study. JRSM cardiovascular disease. Advance online publication. https://doi.org/10.1177/01410768231214341

@article{f579906f616b417a8d6e95c60d173151,

title = "ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study",

author = "Gie Ken-Dror and Pankaj Sharma and {Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators} and {Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group}",

year = "2023",

month = dec,

day = "12",

doi = "10.1177/01410768231214341",

language = "English",

journal = "JRSM cardiovascular disease",

issn = "2048-0040",

}

Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators & Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group 2023, 'ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study', JRSM cardiovascular disease. https://doi.org/10.1177/01410768231214341

ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study. / Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group.
In: JRSM cardiovascular disease, 12.12.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination

T2 - a case–control study

AU - Ken-Dror, Gie

AU - Sharma, Pankaj

AU - Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators

AU - Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group

PY - 2023/12/12

Y1 - 2023/12/12

U2 - 10.1177/01410768231214341

DO - 10.1177/01410768231214341

M3 - Article

SN - 2048-0040

JO - JRSM cardiovascular disease

JF - JRSM cardiovascular disease

ER -

Bio-Repository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) collaborators, Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group. ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case–control study. JRSM cardiovascular disease. 2023 Dec 12. Epub 2023 Dec 12. doi: 10.1177/01410768231214341